

## REMARKS

Claims 1-13 are pending. Claims 8-13 have been withdrawn. Claim 1 has been amended to further define Applicants' invention. Claim 1 is in independent form. Favorable reconsideration and allowance of the subject application are respectfully requested in view of the following comments.

Claim 1 has been amended to include a disintegrant selected from the group consisting of sodium starch glycolate, crosslinked polyvinylpyrrolidone, crosslinked carboxymethylcellulose, and mixtures thereof. Support for this amendment can be found, for example, on page 3, lines 15-17 of the specification. As such, no new matter has been introduced by way of this amendment.

Claims 1-6 stand rejected under 35 U.S.C. § 102(b) as allegedly being obvious over Canadian Patent No. 1,336,687 ("*Tencza et al.*"). Claim 7 stands rejected under 35 U.S.C. § 103(a) as allegedly being obvious over *Tencza et al.* Applicants respectfully traverse these rejections, in view of the comments set forth below.

Among the noteworthy features of the solid pharmaceutical dosage form recited in amended Claim 1 is a disintegrant selected from the group consisting of sodium starch glycolate, crosslinked polyvinylpyrrolidone, crosslinked carboxymethylcellulose, and mixtures thereof.

*Tencza et al.* discloses a process for preparing tablets, wherein ibuprofen, acetaminophen and caffeine are each separately granulated, combined into a mixture and then manufactured into tablets from the mixture. A granulating solution is employed to prepare the granulation, which includes a binder, such as corn starch, that becomes incorporated in the granulation. *See Tencza et al.*, p. 8, lines 8-10 and p. 14, lines 28-32 and p. 16, lines 13 and 14.

*Tencza et al.* further discloses a comparative composition where ibuprofen, acetaminophen, caffeine and microcrystalline cellulose are prepared. The caffeine in the composition is in powder form or granular form and has a particle size of 20 mesh to 100 mesh.

However, Applicants' respectfully submit that the composition of *Tencza et al.* does not include a disintegrant selected from the group consisting of sodium starch glycolate, crosslinked polyvinylpyrrolidone, crosslinked carboxymethylcellulose, and mixtures thereof, as set forth in Claim 1 of the present application.

Accordingly, Claim 1 is patentable over *Tencza et al.*

Claims 2-7 directly or indirectly depend from Claim 1. For at least the same reasons discussed above for Claim 1, Claims 2-7 are patentable over *Tencza et al.*

In view of the foregoing remarks, Applicant respectfully requests favorable reconsideration and allowance of the claims in the present application.

Applicants' undersigned attorney may be reached in our office by telephone at (732) 524-1767. All correspondence should continue to be directed to our below listed address.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Account No. 10-0750/MCP5013NP/VT.

Respectfully submitted,

/Victor Tsu/

Victor Tsu  
Registration No. 46,185  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
Dated: August 13, 2007